Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Haloperidol | 15 | 2019 | 36 | 4.040 |
Why?
|
| Antipsychotic Agents | 10 | 2020 | 81 | 3.380 |
Why?
|
| Antifungal Agents | 10 | 2016 | 169 | 2.570 |
Why?
|
| Receptors, Dopamine D2 | 8 | 2020 | 83 | 2.550 |
Why?
|
| Azepines | 6 | 2019 | 22 | 2.440 |
Why?
|
| Quinolines | 12 | 2013 | 76 | 2.350 |
Why?
|
| Pyridines | 5 | 2021 | 134 | 2.250 |
Why?
|
| Receptor, Serotonin, 5-HT1A | 5 | 2021 | 17 | 2.180 |
Why?
|
| Piperazines | 5 | 2021 | 117 | 2.110 |
Why?
|
| Structure-Activity Relationship | 26 | 2021 | 491 | 1.930 |
Why?
|
| Receptors, Serotonin | 5 | 2021 | 25 | 1.920 |
Why?
|
| Receptors, sigma | 6 | 2019 | 16 | 1.640 |
Why?
|
| Fungi | 7 | 2016 | 103 | 1.590 |
Why?
|
| Indoles | 9 | 2014 | 178 | 1.510 |
Why?
|
| Ligands | 11 | 2021 | 387 | 1.120 |
Why?
|
| Isoquinolines | 2 | 2019 | 50 | 1.090 |
Why?
|
| Molecular Structure | 14 | 2021 | 560 | 0.990 |
Why?
|
| Alkaloids | 8 | 2008 | 46 | 0.970 |
Why?
|
| Behavior, Animal | 3 | 2020 | 369 | 0.960 |
Why?
|
| Apomorphine | 4 | 2020 | 14 | 0.930 |
Why?
|
| Quinolinium Compounds | 2 | 2013 | 9 | 0.840 |
Why?
|
| Catalepsy | 5 | 2019 | 9 | 0.800 |
Why?
|
| Chromatography, High Pressure Liquid | 5 | 2019 | 458 | 0.770 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2021 | 1112 | 0.710 |
Why?
|
| Drug Design | 5 | 2013 | 183 | 0.690 |
Why?
|
| Butyrophenones | 3 | 2011 | 8 | 0.690 |
Why?
|
| Serotonin Antagonists | 1 | 2021 | 24 | 0.690 |
Why?
|
| Animals | 30 | 2020 | 16695 | 0.670 |
Why?
|
| Anti-Bacterial Agents | 3 | 2013 | 415 | 0.640 |
Why?
|
| Microbial Sensitivity Tests | 8 | 2016 | 232 | 0.640 |
Why?
|
| Phenylcarbamates | 1 | 2019 | 2 | 0.630 |
Why?
|
| Amylose | 1 | 2019 | 5 | 0.630 |
Why?
|
| Indenes | 1 | 2019 | 4 | 0.630 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2016 | 22 | 0.500 |
Why?
|
| Receptors, Dopamine D4 | 2 | 2014 | 16 | 0.490 |
Why?
|
| Anti-Infective Agents | 2 | 2006 | 74 | 0.460 |
Why?
|
| Bacteria | 4 | 2013 | 285 | 0.460 |
Why?
|
| Tropanes | 1 | 2014 | 7 | 0.440 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 979 | 0.440 |
Why?
|
| Vero Cells | 5 | 2013 | 109 | 0.440 |
Why?
|
| Rats | 11 | 2019 | 3701 | 0.430 |
Why?
|
| Psychology, Experimental | 1 | 2014 | 2 | 0.430 |
Why?
|
| Acrylamides | 1 | 2014 | 15 | 0.430 |
Why?
|
| Dopamine Antagonists | 1 | 2014 | 48 | 0.430 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2019 | 1737 | 0.420 |
Why?
|
| Cryptococcus | 1 | 2013 | 10 | 0.420 |
Why?
|
| Sulfhydryl Compounds | 1 | 2013 | 49 | 0.410 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2013 | 110 | 0.380 |
Why?
|
| Stereoisomerism | 5 | 2019 | 166 | 0.380 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2012 | 15 | 0.380 |
Why?
|
| Benzothiazoles | 1 | 2012 | 26 | 0.370 |
Why?
|
| Mice | 9 | 2020 | 6490 | 0.370 |
Why?
|
| Biological Products | 1 | 2013 | 91 | 0.370 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 60 | 0.360 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 61 | 0.360 |
Why?
|
| Carbolines | 1 | 2011 | 17 | 0.350 |
Why?
|
| Indole Alkaloids | 7 | 2013 | 14 | 0.310 |
Why?
|
| Humans | 19 | 2021 | 42163 | 0.300 |
Why?
|
| Clozapine | 4 | 2014 | 17 | 0.300 |
Why?
|
| Antioxidants | 1 | 2012 | 439 | 0.290 |
Why?
|
| Piperidines | 3 | 2004 | 80 | 0.260 |
Why?
|
| Butanones | 1 | 2006 | 5 | 0.250 |
Why?
|
| Cell Survival | 3 | 2019 | 934 | 0.250 |
Why?
|
| Oxidative Stress | 1 | 2012 | 990 | 0.250 |
Why?
|
| Magnetic Resonance Spectroscopy | 4 | 2010 | 300 | 0.250 |
Why?
|
| Pyrrolidines | 1 | 2006 | 30 | 0.250 |
Why?
|
| Basal Ganglia Diseases | 1 | 2003 | 6 | 0.210 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2003 | 12 | 0.210 |
Why?
|
| Protein Binding | 3 | 2019 | 1076 | 0.200 |
Why?
|
| Radioligand Assay | 4 | 2004 | 66 | 0.200 |
Why?
|
| Male | 10 | 2020 | 22779 | 0.200 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 1993 | 77 | 0.190 |
Why?
|
| Molecular Probes | 1 | 2002 | 23 | 0.190 |
Why?
|
| Carboxylic Ester Hydrolases | 2 | 2014 | 57 | 0.190 |
Why?
|
| Binding Sites | 3 | 2016 | 670 | 0.180 |
Why?
|
| Carrier Proteins | 1 | 2003 | 318 | 0.180 |
Why?
|
| Stereotyped Behavior | 3 | 2008 | 23 | 0.180 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2019 | 147 | 0.170 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1554 | 0.160 |
Why?
|
| Nitrogen | 1 | 2000 | 83 | 0.160 |
Why?
|
| Tissue Distribution | 2 | 2019 | 230 | 0.150 |
Why?
|
| Cisplatin | 1 | 2019 | 91 | 0.150 |
Why?
|
| Brain | 3 | 2019 | 1452 | 0.140 |
Why?
|
| Schizophrenia | 1 | 2019 | 91 | 0.140 |
Why?
|
| Platelet Aggregation | 2 | 1993 | 21 | 0.130 |
Why?
|
| Isomerism | 2 | 2006 | 65 | 0.130 |
Why?
|
| Dopamine Agents | 1 | 2016 | 28 | 0.120 |
Why?
|
| Opportunistic Infections | 1 | 2016 | 10 | 0.120 |
Why?
|
| Mycoses | 1 | 2016 | 31 | 0.120 |
Why?
|
| Cryptococcus neoformans | 2 | 2010 | 62 | 0.120 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 1993 | 29 | 0.120 |
Why?
|
| Plasmodium falciparum | 2 | 2006 | 146 | 0.110 |
Why?
|
| Receptor, Serotonin, 5-HT2B | 1 | 2014 | 7 | 0.110 |
Why?
|
| Candida albicans | 2 | 2010 | 173 | 0.110 |
Why?
|
| Binding, Competitive | 1 | 2014 | 107 | 0.110 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 2598 | 0.110 |
Why?
|
| Benzodiazepines | 1 | 2014 | 19 | 0.110 |
Why?
|
| Mitosporic Fungi | 2 | 2005 | 5 | 0.110 |
Why?
|
| Cricetulus | 1 | 2014 | 82 | 0.110 |
Why?
|
| CHO Cells | 1 | 2014 | 123 | 0.110 |
Why?
|
| Kinetics | 3 | 2008 | 698 | 0.110 |
Why?
|
| Posture | 1 | 2014 | 61 | 0.100 |
Why?
|
| Cricetinae | 1 | 2014 | 241 | 0.100 |
Why?
|
| Basidiomycota | 1 | 2013 | 12 | 0.100 |
Why?
|
| Pyridinium Compounds | 1 | 1993 | 27 | 0.100 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 45 | 0.100 |
Why?
|
| Arachidonic Acid | 1 | 1993 | 35 | 0.100 |
Why?
|
| Hand Strength | 1 | 2014 | 39 | 0.100 |
Why?
|
| Amides | 1 | 2014 | 72 | 0.100 |
Why?
|
| Blood Platelets | 1 | 1993 | 80 | 0.100 |
Why?
|
| Collagen | 1 | 1993 | 178 | 0.100 |
Why?
|
| Cyclic AMP | 1 | 1993 | 135 | 0.090 |
Why?
|
| Cyclization | 2 | 2010 | 49 | 0.090 |
Why?
|
| Receptors, Dopamine | 1 | 2011 | 30 | 0.090 |
Why?
|
| Indicators and Reagents | 2 | 2006 | 59 | 0.090 |
Why?
|
| Substrate Specificity | 1 | 2012 | 217 | 0.090 |
Why?
|
| Avoidance Learning | 1 | 2012 | 68 | 0.090 |
Why?
|
| Motor Activity | 1 | 2014 | 438 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 206 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2012 | 106 | 0.090 |
Why?
|
| Maximum Tolerated Dose | 1 | 2010 | 11 | 0.090 |
Why?
|
| Aspergillus fumigatus | 1 | 2010 | 13 | 0.090 |
Why?
|
| Protein Methyltransferases | 1 | 2010 | 6 | 0.080 |
Why?
|
| Protein Prenylation | 1 | 2010 | 10 | 0.080 |
Why?
|
| Droperidol | 1 | 2010 | 3 | 0.080 |
Why?
|
| Bromocriptine | 1 | 2010 | 6 | 0.080 |
Why?
|
| Liver | 1 | 1993 | 503 | 0.080 |
Why?
|
| Calcium | 1 | 1993 | 487 | 0.080 |
Why?
|
| Candidiasis | 1 | 2010 | 86 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 1058 | 0.080 |
Why?
|
| Cell Death | 2 | 2014 | 277 | 0.080 |
Why?
|
| Fibroblasts | 1 | 2011 | 278 | 0.080 |
Why?
|
| Blood-Brain Barrier | 1 | 2010 | 167 | 0.080 |
Why?
|
| Lethal Dose 50 | 1 | 2008 | 32 | 0.070 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 55 | 0.070 |
Why?
|
| Antiprotozoal Agents | 1 | 2008 | 33 | 0.070 |
Why?
|
| Antiparasitic Agents | 1 | 2006 | 10 | 0.070 |
Why?
|
| Leishmania donovani | 1 | 2006 | 18 | 0.060 |
Why?
|
| Chemistry, Physical | 1 | 2006 | 50 | 0.060 |
Why?
|
| Chemical Phenomena | 1 | 2006 | 56 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 181 | 0.060 |
Why?
|
| Antimalarials | 1 | 2006 | 63 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 98 | 0.060 |
Why?
|
| Thioxanthenes | 1 | 2004 | 1 | 0.050 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2004 | 33 | 0.050 |
Why?
|
| Dopamine Agonists | 1 | 2003 | 34 | 0.050 |
Why?
|
| Rabbits | 2 | 1993 | 292 | 0.050 |
Why?
|
| Cell Line | 1 | 2006 | 1416 | 0.050 |
Why?
|
| Psychomotor Performance | 1 | 2003 | 156 | 0.050 |
Why?
|
| Guinea Pigs | 2 | 2000 | 144 | 0.050 |
Why?
|
| Alkylation | 2 | 1999 | 11 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1999 | 44 | 0.040 |
Why?
|
| Fatty Acids | 1 | 1999 | 134 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 1999 | 249 | 0.030 |
Why?
|
| Models, Chemical | 1 | 1999 | 205 | 0.030 |
Why?
|
| Temperature | 1 | 1999 | 314 | 0.030 |
Why?
|
| Models, Biological | 1 | 2000 | 711 | 0.030 |
Why?
|
| Cell Membrane | 2 | 1994 | 400 | 0.030 |
Why?
|
| Methylation | 2 | 2010 | 118 | 0.030 |
Why?
|
| Amines | 1 | 1994 | 40 | 0.030 |
Why?
|
| Oxalates | 1 | 1993 | 3 | 0.030 |
Why?
|
| Calcimycin | 1 | 1993 | 11 | 0.030 |
Why?
|
| Rana pipiens | 1 | 1993 | 62 | 0.030 |
Why?
|
| Thrombin | 1 | 1993 | 28 | 0.030 |
Why?
|
| 1-Methyl-4-phenylpyridinium | 1 | 1993 | 28 | 0.030 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1993 | 14 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1993 | 282 | 0.020 |
Why?
|
| Imidazoles | 1 | 1993 | 138 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 55 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 875 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2010 | 151 | 0.020 |
Why?
|
| Drug Stability | 1 | 2010 | 127 | 0.020 |
Why?
|
| Swine | 1 | 2010 | 205 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 420 | 0.020 |
Why?
|
| Time Factors | 1 | 1993 | 1848 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1420 | 0.020 |
Why?
|
| Female | 1 | 1993 | 24018 | 0.010 |
Why?
|
| Radioisotope Dilution Technique | 1 | 1985 | 2 | 0.000 |
Why?
|
| Iodine Radioisotopes | 1 | 1985 | 39 | 0.000 |
Why?
|
| Plants, Medicinal | 1 | 1985 | 60 | 0.000 |
Why?
|